Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning
24 Abril 2023 - 9:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage
bioelectronic medicine and wellness company, today announced that
the Air Force Research Laboratories (AFRL) reported data from its
study on the ability of gammaCore non-invasive vagus nerve
stimulation (nVNS) to improve second language learning. The study
was conducted at the Defense Language Institute (DLI) in Monterey,
CA, the US Department of Defense’s premier language school. The
study was supported by Defense Advanced Research Projects Agency
(DARPA)/AFRL within the DARPA Targeted Neuroplasticity Training
(TNT) program.
The study recruited 36 student participants from DLI’s Arabic
school house (nVNS = 18 & Sham = 18). Each subject was assessed
on day 1 to establish a baseline. On days 2-4, two 2-minute
gammaCore (nVNS) stimulation treatments were self-administered by
the subject, each before and after training. Assessments were taken
each treatment day, and on day 5 where there was no treatment,
assessments were conducted to assess possible carryover effects.
The study showed a significant positive effect of gammaCore (nVNS)
over sham (p=0.025) on language recall, thereby suggesting
gammaCore’s (nVNS) ability to significantly improve the recall of a
foreign language compared to sham. The improvement achieved through
gammaCore (nVNS) treatment on days 2-4 was maintained on day 5
demonstrating that the recall advantage that emerged during
training was sustained after the completion of treatment.
All participants completed the AFRL Mood Questionnaire on each
day (1-5) of the study. From the a priori-selected three scales of
the AFRL Mood Questionnaire, participants receiving gammaCore
(nVNS) showed significant increases in energy (p=0.036) and focus
(p=0.001) over the course of each training session compared to sham
participants, and their calm score also trended towards an
improvement from gammaCore (nVNS).
Dr. Richard McKinley, of the Air Force’s 711th Human
Performance Wing, Human Effectiveness Directorate and an
investigator of the study, commented, “We are pleased to have
successfully completed the first randomized, double-blind
sham-controlled trial demonstrating that gammaCore (nVNS)
accelerated the learning of Arabic vocabulary in students at the
Defense Language Institute. Equally impressive were the
improvements in the subject’s energy and mood despite the rigors of
the training program. This study compliments our findings that
suggest gammaCore (nVNS) could be a valuable tool to enhance
warfighter training and resilience in a range of areas.”
“We congratulate and thank the teams at DLI and AFRL for
the dedicated work on this study as well as DARPA for their
sponsoring the study,” commented Dr. Peter Staats, Chief
Medical Officer of electroCore. “Cognitive performance and skill
acquisition are central to the mission of many institutions in a
wide variety of sectors including educational, commercial, and
military. This study suggests gammaCore (nVNS) could accelerate
these efforts.”
About The Air Force Research Laboratory
(AFRL)The Air Force Research Laboratory is the primary
scientific research and development center for the Department of
the Air Force. AFRL plays an integral role in leading the
discovery, development, and integration of affordable warfighting
technologies for our air, space, and cyberspace force. With a
workforce of more than 11,500 across nine technology areas and 40
other operations across the globe, AFRL provides a diverse
portfolio of science and technology ranging from fundamental to
advanced research and technology development. For more information,
visit: www.afresearchlab.com.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About gammaCore™ gammaCore™ (nVNS) is the
first non-invasive, hand-held medical therapy applied at the neck
to treat migraine and cluster headache through the utilization of a
mild electrical stimulation to the vagus nerve that passes through
the skin. Designed as a portable, easy-to-use technology, gammaCore
is self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore™ is intended to provide non-invasive vagus nerve
stimulation (nVNS) on the side of the neck for preventive treatment
of migraine and the acute treatment of pain associated with
migraine in patients 12 and older. gammaCore is also indicated for
adjunctive use for preventive treatment of cluster headache, acute
treatment of episodic cluster headache, and treatment of hemicrania
continua and paroxysmal hemicrania in adult patients.
gammaCore should not be used by people with an active
implantable medical device. Please refer to gammaCore.com or the
Instructions for Use for complete safety information, including
indications, contraindications, warnings, cautions, and
instructions.
For more information, please visit gammaCore.com
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to,
statements regarding the results from investigator-initiated
trials, anticipated results and timing of clinical trials being
conducted with gammaCore (nVNS), electroCore's business prospects,
its sales and marketing and product development plans, future cash
flow projections, anticipated costs, its product portfolio or
potential markets for its technologies, the availability and impact
of payor coverage, the potential of nVNS generally and gammaCore in
particular to accelerate second language learning, improve focus
and decrease fatigue, and other statements that are not historical
in nature, particularly those using terminology such as
"anticipates," "expects," "believes," "intends," other words of
similar meaning, derivations of such words and the use of future
dates. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to obtain additional financing
necessary to continue electroCore's business, sales and marketing
and product development plans, the uncertainties inherent in the
development of new products or technologies, the ability to
successfully commercialize gammaCore™, competition in the industry
in which electroCore operates and general market conditions. The
results of earlier preclinical studies and clinical trials may not
be predictive of results of future preclinical studies, clinical
trials, or commercial success. All forward-looking statements are
made as of the date of this press release, and electroCore
undertakes no obligation to update forward-looking statements or to
update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by
law. Investors should refer to all information set forth in this
document and should also refer to the disclosure of risk factors
set forth in the reports and other documents electroCore files with
the SEC, available at www.sec.gov.Contact:Rich
CockrellCG Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024